Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature. 2017;546(7659):528-32.
Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. Sci Adv. 2017;3(2):e1601944.
Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections. J Med Chem 2016, E-pub.
Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. Expert Opin Ther Pat 2016, 26 (2), 175-97.
Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. Chem Med Chem 2016, 11(4), 367-73.
A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug resistant uropathogenic Escherichia coli ST131, J Inf Dis 2013, 208(6), 921-8.
Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem 2012, 55(8), 3945-59.
Treatment and Prevention of Urinary Tract Infection with Orally Active Mannoside FimH Inhibitors. Sci Trans Med, 2011, 3(109), 1-10.
Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 2010, 53(12):4779-92.